Side Effects Involving the Heart in Women With Breast Cancer Receiving Doxorubicin and Trastuzumab

Completed

Conditions studied: Breast Cancer, Cardiac Toxicity, Cardiovascular Complications

In brief

RATIONALE: Studying samples of blood and tissue in the laboratory from women receiving doxorubicin and trastuzumab for breast cancer may help doctors learn more about changes that occur in DNA and identify biomarkers for increased risk of cardiac effects. PURPOSE: This clinical trial is studying side effects involving the heart in women with breast cancer receiving doxorubicin and trastuzumab.

Key facts

Study ID

NCT00875238

Run by

Vanderbilt University

People needed

133

Starts

2008-06-01

Expected to finish

2015-03-01

Last updated by the study team

2018-02-19

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of Louisville James Graham Brown Cancer Center — Louisville, Kentucky, United States
• Vanderbilt Heart One Hundred Oaks — Nashville, Tennessee, United States
• MBCCOP - Meharry Medical College - Nashville — Nashville, Tennessee, United States
• Vanderbilt-Ingram Cancer Center — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.